Energy Consumption and Cardiorespiratory Load During Overground Gait Training With a Wearable Exoskeleton After Stroke

Energy Consumption and Cardiorespiratory Load During Overground Gait Training With a Wearable Exoskeleton After Stroke: the Effect of the Level of Swing Assistance

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03367091

Enrollment

Registered

2017-12-08

Start date

2018-07-09

Completion date

2018-12-31

Last updated

2019-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Keywords

Wearable Exoskeleton, Stroke, Energy Consumption, Cardiorespiratory Load

Brief summary

To investigate acute metabolic and cardiorespiratory responses during overground gait training with a wearable exoskeleton in persons after stroke

Detailed description

RESEARCH AIMS: * To investigate the effect of the level of swing assistance on the acute metabolic and cardiorespiratory responses during overground gait training with a wearable exoskeleton in persons after stroke * To investigate if there is an interaction-effect between the level of swing assistance and the duration of walking * To compare the exercise intensity to aerobic training recommendations STUDY DESIGN: An experimental, 1-group trial with randomized crossover design. PATIENT RECRUITMENT: Participants will be recruited at the AZ Herentals (Herentals, Belgium). LOCATION: The trial will be conducted at the REVAlution Center (Herentals, Belgium). ELIGIBILITY CRITERIA: See section Eligibility PROCEDURES: Before the start of the study, informed consent and baseline patient characteristics will be collected. Next, participants will be measured during three training sessions with the Ekso GT SmartAssist: * 20-minute training with high swing assistance * 20-minute training with neutral swing assistance * 20-minute training with high swing resistance Trainings will be performed on a separate day in a randomized order (within one week and controlled for time of day). Following settings will be used in all three conditions: sitting program (Min lean); standing program (Auto lean); step initiation program (ProStep+), training mode (Off), SmartAssist option (2Free); and stance support (Low). The level of stance support and swing assistance will be set symmetrically for the affected and non-affected side. During training, participants will walk back and forth at a self-selected walking speed in a 30m hall way using a cane at the non-affected side. Prior to the experimental conditions, participants will have had three training sessions in the Ekso GT. RESTRICTIONS & PROHIBITIONS: Participants will be instructed to not consume food, alcohol, caffeine or nicotine at least 3h prior to the intervention. Usual medication intake will be allowed with small amounts of water. MATERIALS: The Ekso GT robotic exoskeleton with SmartAssist (Ekso Bionics Inc., USA) will be used during the overground training sessions. A flexible facemask (adult facemask, small/medium, Cortex, Germany), lightweight chest carrying gas analysis system (Metamax 3B, Cortex, Germany) and Bluetooth heart rate belt (Polar H7, Polar Electro, Finland) will be used to measure metabolic and cardiorespiratory parameters. At the start of each measurement, gas (room air and reference gas (17.4% O2 and 5.1% CO2)) and volume (3L syringe) calibrations of the breath-by-breath gas analysis system will be performed in accordance with the manufacturer's instructions. OUTCOMES: See section Outcome Measures DATA-ANALYSES: Descriptive statistics will be calculated for baseline patient characteristics. To investigate the effect of level of swing assistance and duration, a repeated measures ANOVA (within factor duration and within factor assistance level) will be conducted (interaction-effect time x duration, main effect assistance level and main effect duration). In case of significant differences, posthoc analyses will be interpreted. The walking speed will be considered as a covariate in the ANOVA analysis (in case significant different between conditions). Significance level will be set at 5%.

Interventions

OTHEREkso GT gait training with high swing assistance

Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at high assistance

OTHEREkso GT gait training with neutral swing assistance

Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at neutral

OTHEREkso GT gait training with high swing resistance

Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at high resistance

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Included will be persons who * Had a stroke * Cannot walk independently or can walk independently on level ground, but still require help on stairs, slopes or uneven surfaces (FAC 0 - 4) Excluded will be persons who * Can walk independently on level ground, stairs, slopes and uneven surfaces (FAC 5) * Have musculoskeletal problems (other than stroke) affecting the ability to walk * Have concurrent pulmonary diseases (e.g. asthma) * Have unstable cardiovascular conditions * Have concurrent neurological diseases (e.g. Parkinson's Disease) * Have communicative and/or cognitive problems affecting the ability to understand or follow instructions * Present contra-indications for using the Ekso GT (according to manufacturer's instructions) * Severe concurrent medical diseases (infections, circulatory, heart or lung, pressure sores) * Severe spasticity (Ashworth 4) * Range of motion restrictions that would prevent a patient from achieving normal, reciprocal gait pattern, or would restrict a patient from completing normal sit-to-stand or stand-to-sit transitions * Bilateral hip flexion \< 110° * Knee flexion contracture \> 12° * Inability to achieve 0° neutral angle dorsiflexion with knee flexion ≤ 12° * Weight ≥ 100 kg * Hip width \< 35.8 cm or \> 45.6 cm * Upper leg length \< 51 cm or \> 61.4 cm * Lower leg length \< 48 cm or \> 63.4 cm * Upper leg length discrepancy \> 0.5 inch (1.3 cm) * Lower leg length discrepancy \> 0.75 inch (1.9 cm) * Unstable spine, unhealed limbs or pelvic fractures * Unhealthy bone density * Heterotopic ossification * Significant contractures * Elbows and shoulders are unable to support crutches, walker or cane * Psychiatric or cognitive situations that may interfere with proper operation of the device

Design outcomes

Primary

Measure	Time frame	Description
Net minute ventilation (VE, L/min) at minute 5 of walking	Minute 5 of 20-minute walking period	The amount of air in- or exhaled per minute (L/min) during walking minus during rest
Net minute ventilation (VE, L/min) at minute 20 of walking	Minute 20 of 20-minute walking period	The amount of air in- or exhaled per minute (L/min) during walking minus during rest
Net minute ventilation (VE, L/min) at minute 15 of walking	Minute 15 of 20-minute walking period	The amount of air in- or exhaled per minute (L/min) during walking minus during rest
Net minute ventilation (VE, L/min) at minute 10 of walking	Minute 10 of 20-minute walking period	The amount of air in- or exhaled per minute (L/min) during walking minus during rest
Net oxygen cost (OC, ml/kg/m) at minute 5 of walking	Minute 5 of 20-minute walking period	Net oxygen consumption (oxygen consumption (ml/kg/min) during walking minus during rest) divided by the walking speed (m/min)
Net oxygen cost (OC, ml/kg/m) at minute 10 of walking	Minute 10 of 20-minute walking period	Net oxygen consumption (oxygen consumption (ml/kg/min) during walking minus during rest) divided by the walking speed (m/min)
Net oxygen cost (OC, ml/kg/m) at minute 15 of walking	Minute 15 of 20-minute walking period	Net oxygen consumption (oxygen consumption (ml/kg/min) during walking minus during rest) divided by the walking speed (m/min)
Net oxygen cost (OC, ml/kg/m) at minute 20 of walking	Minute 20 of 20-minute walking period	Net oxygen consumption (oxygen consumption (ml/kg/min) during walking minus during rest) divided by the walking speed (m/min)
Net heart rate (HR, beats/min) at minute 5 of walking	Minute 5 of 20-minute walking period	Heart rate during walking (beats/min) minus resting heart rate
Net heart rate (HR, beats/min) at minute 10 of walking	Minute 10 of 20-minute walking period	Heart rate during walking (beats/min) minus resting heart rate
Net heart rate (HR, beats/min) at minute 15 of walking	Minute 15 of 20-minute walking period	Heart rate during walking (beats/min) minus resting heart rate
Net heart rate (HR, beats/min) at minute 20 of walking	Minute 20 of 20-minute walking period	Heart rate during walking (beats/min) minus resting heart rate

Secondary

Measure	Time frame	Description
Percentage heart rate reserve (%HRR) at minute 20 of walking	Minute 20 of 20-minute walking period	Heart rate during walking minus during rest divided by predicted heart rate reserve (i.e. predicted maximum heart rate minus resting heart rate)
Metabolic Equivalent of Task (MET) at minute 10 of walking	Minute 10 of 20-minute walking period	Expression of the intensity of walking defined as the oxygen consumption (ml/kg/min) during walking divided by the oxygen consumption (ml/kg/min) in rest
Metabolic Equivalent of Task (MET) at minute 15 of walking	Minute 15 of 20-minute walking period	Expression of the intensity of walking defined as the oxygen consumption (ml/kg/min) during walking divided by the oxygen consumption (ml/kg/min) in rest
Metabolic Equivalent of Task (MET) at minute 20 of walking	Minute 20 of 20-minute walking period	Expression of the intensity of walking defined as the oxygen consumption (ml/kg/min) during walking divided by the oxygen consumption (ml/kg/min) in rest
Metabolic Equivalent of Task (MET) at minute 5 of walking	Minute 5 of 20-minute walking period	Expression of the intensity of walking defined as the oxygen consumption (ml/kg/min) during walking divided by the oxygen consumption (ml/kg/min) in rest
Net Rating of Perceived Exertion (RPE, 6-20) at minute 5 of walking	Minute 5 of 20-minute walking period	Rating of perceived effort, strain and/or fatigue during walking, pointed on a 15-point Borg scale (6-20) during walking minus during rest
Net Rating of Perceived Exertion (RPE, 6-20) at minute 10 of walking	Minute 10 of 20-minute walking period	Rating of perceived effort, strain and/or fatigue during walking, pointed on a 15-point Borg scale (6-20) during walking minus during rest
Net Rating of Perceived Exertion (RPE, 6-20) at minute 15 of walking	Minute 15 of 20-minute walking period	Rating of perceived effort, strain and/or fatigue during walking, pointed on a 15-point Borg scale (6-20) during walking minus during rest
Net Rating of Perceived Exertion (RPE, 6-20) at minute 20 of walking	Minute 20 of 20-minute walking period	Rating of perceived effort, strain and/or fatigue during walking, pointed on a 15-point Borg scale (6-20) during walking minus during rest
Percentage maximal heart rate (%HRmax) at minute 5 of walking	Minute 5 of 20-minute walking period	Heart rate divided by predicted maximum heart rate.
Percentage maximal heart rate (%HRmax) at minute 10 of walking	Minute 10 of 20-minute walking period	Heart rate divided by predicted maximum heart rate.
Percentage maximal heart rate (%HRmax) at minute 15 of walking	Minute 15 of 20-minute walking period	Heart rate divided by predicted maximum heart rate.
Percentage maximal heart rate (%HRmax) at minute 20 of walking	Minute 20 of 20-minute walking period	Heart rate divided by predicted maximum heart rate.
Percentage heart rate reserve (%HRR) at minute 5 of walking	Minute 5 of 20-minute walking period	Heart rate during walking minus during rest divided by predicted heart rate reserve (i.e. predicted maximum heart rate minus resting heart rate)
Percentage heart rate reserve (%HRR) at minute 10 of walking	Minute 10 of 20-minute walking period	Heart rate during walking minus during rest divided by predicted heart rate reserve (i.e. predicted maximum heart rate minus resting heart rate)
Percentage heart rate reserve (%HRR) at minute 15 of walking	Minute 15 of 20-minute walking period	Heart rate during walking minus during rest divided by predicted heart rate reserve (i.e. predicted maximum heart rate minus resting heart rate)

Other

Measure	Time frame	Description
Walking speed (m/min) at minute 5 of walking	Minute 5 of 20-minute walking period	The distance (meters) walked per minute
Walking speed (m/min) at minute 20 of walking	Minute 20 of 20-minute walking period	The distance (meters) walked per minute
Walking speed (m/min) at minute 15 of walking	Minute 15 of 20-minute walking period	The distance (meters) walked per minute
Walking speed (m/min) at minute 10 of walking	Minute 10 of 20-minute walking period	The distance (meters) walked per minute

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026